Information Provided By: 
Fly News Breaks for July 15, 2015
ZGNX
Jul 15, 2015 | 07:18 EDT
Brean Capital raised its price target on Zogenix to $28 from $20 citing the efficacy potential of its drug for Dravet's syndrome. The firm felt its previous assumptions were too conservative and raising them resulted in a higher price target. Brean Capital reiterated its Buy rating on Zogenix shares.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
